Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease

Publisher： Karger

E-ISSN： 1421-9670|44|4|316-325

ISSN： 0250-8095

Source： American Journal of Nephrology, Vol.44, Iss.4, 2016-09, pp. : 316-325

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease

By  

American Journal of Nephrology, Vol. 45, Iss. 5, 2017-03 ,pp. : 380-388

Karger

Access to resources Recommend Favorite

Furosemide Increases the Risk of Hyperparathyroidism in Chronic Kidney Disease

By  

American Journal of Nephrology, Vol. 43, Iss. 6, 2016-05 ,pp. : 421-430

Karger

Access to resources Recommend Favorite

A Comparison of Dosing Regimens of Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in CKD Stages 3 and 4

By  

American Journal of Nephrology, Vol. 26, Iss. 1, 2006-04 ,pp. : 105-114

Karger

Access to resources Recommend Favorite

Chronic Kidney Disease Stages Are Appropriate at All Ages

By  

Blood Purification, Vol. 31, Iss. 1-3, 2011-01 ,pp. : 125-129

Karger

Access to resources Recommend Favorite

Cytokine Dysregulation in Chronic Kidney Disease: How Can We Treat It?

By  

Blood Purification, Vol. 26, Iss. 3, 2008-04 ,pp. : 291-299

Karger

Access to resources Recommend Favorite